J&J chooses an advocate of the “golden age” of vaccines at the Gates Foundation to lead the pipeline into the future
A high-profile player is about to jump onto the world stage of vaccine development at a crucial time for the fast-changing field.
We learned via social media posts that Penny Heaton is transitioning from her role as CEO of the Bill & Melinda Gates Medical Research Institute to global therapeutic area head of vaccines at world player J&J. A spokesperson for the giant pharma outfit tells Endpoints News that Heaton’s new job starts on September 7. And the changeup puts her in a hot seat as the pharma giant evaluates its position in the vaccine world as upstarts — one tied to Pfizer — take control of the multibillion-dollar market for Covid-19 vaccines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.